Skip to content

Esketamine augmentation superior to quetiapine augmentation in treatment‐resistant depression

The Brown University Psychopharmacology Update 2024 DOI: 10.1002/pu.31108 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Open-label Phase 3b trial Peer reviewed
Population Patients with treatment-resistant depression
Intervention Esketamine nasal spray
Topics Depression Esketamine
Key findings Esketamine nasal spray plus an antidepressant was more efficacious than extended-release quetiapine plus an antidepressant in patients with treatment-resistant depression. Both groups improved in remission rates over time, but the esketamine combination showed superior efficacy.

Abstract

A Phase 3b open‐label trial has found that esketamine nasal spray in combination with an antidepressant was more efficacious than extended‐release quetiapine plus an antidepressant in patients with treatment‐resistant depression. Both patient groups experienced improved remission rates over time.

Comparable studies

Other non-randomized and open-label trials on esketamine for depression, most cited first.

Study Year Design Participants
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression Adults (≥ 18 years) with treatment-resistant depression 2020 Phase 3, open-label, multicenter, long-term study n = 802
Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study Adults with treatment-resistant depression 2023 Open-label, long-term extension study n = 1,148
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study. Adults with treatment-resistant depression who participated in ≥1 of 6 phase 3 parent... 2025 Open-label, single-arm long-term extension study n = 1,148
Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder: Open-Label Single-Arm Pilot Study Patients with treatment-resistant major depressive disorder and comorbid post-traumatic... 2022 Open-label, single-arm, retrospective pilot study n = 11
Rapid and long-lasting effects of subcutaneous esketamine on suicidality: An open-label study in patients with treatment-resistant depression. Treatment-resistant depressive patients 2024 Open-label clinical trial n = 18

Related reading

Explore topics

Depression Esketamine

By condition and practice

Esketamine for depression Ketamine for depression